// ABOUT · ANDREW WYATT

Clarity when it counts. Thirty years in one place.

B2B SaaS operator. Four exits. Growth-stage advisor, fractional executive and NED. Based in London.

Andrew Wyatt, Principal, Ortent Advisory Ltd

Andrew Wyatt has spent thirty years building, running and selling B2B software companies. Four successful exits: Lotus to IBM ($3.5B), Paragon Software to Phone.com ($500M, European record exit on $10M revenues), Apertio to Nokia ($240M), and Clearswift to Lyceum Capital ($50M).

Most recently, Chief Growth Officer at Sapio Sciences and Sigmatic Sciences (GHO Capital), the life sciences informatics and AI platform. Before Sapio, Chief Operating Officer at Lumeon, the deterministic care-orchestration platform used at NYC Health + Hospitals, Kaiser Permanente, USC Keck, BUPA and Nuffield.

Ortent Advisory Ltd is the vehicle for the next stage. Advisory, fractional executive and board work with growth-stage life sciences and AI SaaS companies. Selective. Named engagements. Written outputs.

// THE ORTENT PRINCIPLE

Every advisory engagement produces something written. Named deliverables. No slide theatre. Written outputs a board can act on. The audience is narrow: growth-stage B2B SaaS, life sciences informatics, digital health, and AI SaaS. Between £5m and £30m ARR, post-Series B or PE-backed.

What "clarity when it counts" means in practice.

Every advisory engagement produces something written. A Sprint delivers a board-ready answer to one question. A 90-day Diagnostic delivers twenty answered questions and a target operating model. Advisory produces working notes, board-pack reviews and quarterly summaries. Nothing lives only in someone's head after Andrew has left the room.

The work is grounded in what a growth-stage board actually needs. Not consulting frameworks that describe the problem. Working artefacts that resolve it. The five interactive diagnostics on this site are drawn directly from that operating experience. They are free because they are the thinking, not the engagement.

The audience is narrow. Growth-stage B2B SaaS. Life sciences informatics, digital health, and the AI SaaS companies serving both. Between £5m and £30m ARR, post-Series B, or PE-backed. This is where thirty years of pattern recognition lands the hardest.

The framework is public. The verdict is the work.

The career at a glance.

Current · Advisory
  1. Most recent

    Principal, Ortent Advisory Ltd

    Founded to consolidate advisory, fractional and board work. Growth-stage life sciences and AI SaaS.

Executive roles · 2013 to 2026
  1. Nov 2022 – Apr 2026

    Chief Growth Officer, Sapio Sciences & Sigmatic Sciences (GHO Capital)

    Life sciences lab informatics (ELN/LIMS) and AI-driven automation. Built European and Asian operations from scratch. Lighthouse deals at AstraZeneca, Wellcome Sanger Institute, Nature Metrics and A*STAR. Tripled ARR over four years. Built the AI ecosystem with NVIDIA, AWS, Elsevier and CAS. SI programme with Cognizant, Accenture, EY, CapGemini and EPAM: $250M+ pipeline, 3x win rates, 150% ARR uplift.

  2. Jan 2015 – Nov 2022

    Chief Operating Officer & Board Director, Lumeon

    Care journey orchestration for UK and US health systems. 4x revenue growth to $12M. Team from 30 to 130. President, Lumeon Inc. Led US market entry with landmark deals at Kaiser Permanente, USC Keck, NYC Health + Hospitals, Optum and Reliant. Partnerships with EPIC and Cerner. Secured over $80M in funding.

  3. Aug 2013 – Oct 2014

    Vice President, Strategy, BroadSoft (NASDAQ: BSFT)

    Repositioned BroadSoft as an enterprise communications platform. Drove 100% Cloud revenue growth to $25M. Led acquisition and integration of SDD.

The four exits · 1995 to 2011
  1. Exit four · 2011

    Clearswift, sold to Lyceum Capital for $50M

    Chief Operating Officer. Led the turnaround from loss-making to profitable. Grew core revenues from $25M to $30M in eighteen months. 17,000 clients in 50 countries including BAE, Hitachi and T-Mobile. IT security and data-protection.

  2. Exit three · 2009

    Apertio, sold to Nokia for $240M

    Chief Product Operations Officer, Interim CEO and Board Director. Grew revenues from $600K to over $30M in four years. Scaled from 30 UK staff to 250 globally. Sunday Times Tech Track 100 Best Management Team, 2006. As interim CEO, chaired the board's dual-track exit evaluation and delivered the sale to Nokia. Mobile subscriber data management for global carriers.

  3. Exit two · 2000

    Paragon Software, sold to Phone.com for $500M

    VP Marketing and Product Management. European record exit on $10M revenues. Post-acquisition, directed the global Synchronisation business at Phone.com and led Openwave's EMEA market strategy across $175M revenues.

  4. Exit one · 1995

    Lotus Development Corp, sold to IBM for $3.5B

    Director, Product Management and Design for Spreadsheets and SmartSuite. Boston. Doubled Lotus Spreadsheet market share to 25% through the strategic refocus that preceded the IBM acquisition.

The current work.

Three surfaces.

Five offers

Ortent services

Sprint, 90-day Diagnostic, Advisory, Fractional CGO, NED. Five ways to engage, laid out on one page.

 Free artefacts

The tools

Five interactive diagnostics, four downloadable whitepapers, four Claude prompts. No email capture. The frameworks in play.

 Weekly

The Growth Chair

Board-facing commentary on growth-stage SaaS, life sciences and AI. Published on Substack and inside LinkedIn.

What people say.

// LIFE SCIENCES ECOSYSTEM ENDORSEMENT
"The partner program Andrew built at Sapio set a new bar for what life sciences software ecosystems can look like. He made it easy for global services partners like Cognizant to invest, deliver, and grow alongside the platform, which is rarer than it should be."
Venkat Kannan, CDS and Lab Automation Lead NA, Cognizant
Venkat Kannan CDS and Lab Automation Lead NA · Cognizant LinkedIn →

Fifteen minutes to see if this is a fit. No pitch, no deck.

Contact Andrew